Cargando…
Open-label, multicenter, randomized phase II study on docetaxel plus bevacizumab or pemetrexed plus bevacizumab for treatment of elderly (aged ≥75 years) patients with previously untreated advanced non-squamous non-small cell lung cancer: TORG1323
BACKGROUND: The effectiveness of bevacizumab monotherapy in elderly patients with non-squamous non-small cell lung cancer (NSCLC) is unclear. The efficacy of the combinations for elderly patients was explored. METHODS: Untreated patients (≥75 years; performance status 0–1) with stage IIIB, IV, or re...
Autores principales: | Kozuki, Toshiyuki, Nogami, Naoyuki, Hataji, Osamu, Tsunezuka, Yoshio, Seki, Nobuhiko, Harada, Toshiyuki, Fujimoto, Nobukazu, Bessho, Akihiro, Takamura, Kei, Takahashi, Kazuhisa, Satouchi, Miyako, Kato, Terufumi, Shukuya, Takehito, Yamashita, Natsumi, Okamoto, Hiroaki, Shinkai, Tetsu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354128/ https://www.ncbi.nlm.nih.gov/pubmed/32676310 http://dx.doi.org/10.21037/tlcr.2020.03.29 |
Ejemplares similares
-
Feasibility study of first-line chemotherapy using Pemetrexed and Bevacizumab for advanced or recurrent nonsquamous non-small cell lung cancer in elderly patients: TORG1015
por: Kozuki, Toshiyuki, et al.
Publicado: (2016) -
Randomized, Phase II study of pemetrexed plus bevacizumab versus pemetrexed alone after treatment with cisplatin, pemetrexed, and bevacizumab in advanced non‐squamous, non‐small cell lung cancer: TORG (thoracic oncology research group) 1321
por: Kasai, Takashi, et al.
Publicado: (2023) -
Phase II study of pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab in Japanese patients with non-squamous non-small cell lung cancer
por: YOKOI, TAKASHI, et al.
Publicado: (2014) -
Bevacizumab plus platinum-based chemotherapy in advanced non-squamous non-small-cell lung cancer: a randomized, open-label phase 2 study (CLEAR)
por: Udagawa, Hibiki, et al.
Publicado: (2021) -
Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study
por: Nakano, Takashi, et al.
Publicado: (2020)